Clinical outcomes and toxicity of estramustine phosphate (EP) addition to docetaxel (D) as first-line therapy for castration-resistant prostate cancer (CRPC): A cumulative analysis on 243 patients (pts) from two randomized phase II trials / Caffo, O; Sava, T; Zustovich, F; Lodde, M; Sacco, C; Lo Re, G; Buti, S; Basso, U; Gamucci, T; Facchini, G; Perin, A; Segati, R; Russo, L; Veccia, A; Galligioni, E. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 31:6(2013). [10.1200/jco.2013.31.6_suppl.208]

Clinical outcomes and toxicity of estramustine phosphate (EP) addition to docetaxel (D) as first-line therapy for castration-resistant prostate cancer (CRPC): A cumulative analysis on 243 patients (pts) from two randomized phase II trials

Buti S;
2013

Clinical outcomes and toxicity of estramustine phosphate (EP) addition to docetaxel (D) as first-line therapy for castration-resistant prostate cancer (CRPC): A cumulative analysis on 243 patients (pts) from two randomized phase II trials / Caffo, O; Sava, T; Zustovich, F; Lodde, M; Sacco, C; Lo Re, G; Buti, S; Basso, U; Gamucci, T; Facchini, G; Perin, A; Segati, R; Russo, L; Veccia, A; Galligioni, E. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 31:6(2013). [10.1200/jco.2013.31.6_suppl.208]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2906886
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact